Enzyme News and Research

RSS

Anti-aromatase phytochemicals in pomegranates reduce hormone-dependent breast cancer

Eating fruit, such as pomegranates, that contain anti-aromatase phytochemicals reduces the incidence of hormone-dependent breast cancer, according to results of a study published in the January issue of Cancer Prevention Research, a journal of the American Association for Cancer Research.

5 Jan 2010

Anti-inflammatory prescription drug reduces the risk of common skin cancer in humans

A widely-available anti-inflammatory prescription drug can reduce the risk of a common skin cancer in humans, according to a researcher at Stanford's School of Medicine.

5 Jan 2010

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.

4 Jan 2010

UI cell membrane protein study may lead to new methods of tracking metastasizing cancer cells

With the discovery of a new type of chemical modification on an important muscle protein, a University of Iowa study improves understanding of certain muscular dystrophies and could potentially lead to new treatments for the conditions.

4 Jan 2010

Bacterial enzyme decreases cocaine desire

A recent study shows that a bacterial protein may help cocaine addicts break the habit.

3 Jan 2010

NeurAxon closes the sale of $8.75 million of unsecured subordinated convertible debentures

NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed the sale of approximately $8.75 million of unsecured subordinated 2.0% convertible debentures that are convertible under specified circumstances into existing class B preferred shares.

29 Dec 2009

DMET genotyping platform screens for 1256 genetic variations in 170 genes

It's the ultimate goal in the treatment of cancer: tailoring a person's therapy based on his or her genetic makeup. While a lofty goal, scientists are steadily moving forward, rapidly exploiting new technologies. Researchers at Georgetown Lombardi Comprehensive Cancer Center report a significant advance in this field of research using a new chip that looks for hundreds of mutations in dozen of genes.

29 Dec 2009

Emerald BioStructures engineers new allosteric small molecule modulators of the PDE4 enzyme

Emerald BioStructures (formerly deCODE biostructures) announced today a publication in the December 27, 2009 advance online issue of Nature Biotechnology, detailing the application of structure-based drug design (SBDD) to engineer new allosteric small molecule modulators of the enzyme phosphodiesterase-4 (PDE4), with reduced side effects. According to the paper, the researchers established the structural basis of PDE4 regulation through crystal structures of the PDE4 regulatory domain in contact with small molecules.

29 Dec 2009

Sudden worldwide increase in antibiotic-resistant bacterium, a cause for concern

A sudden worldwide increase in an antibiotic-resistant bacterium is cause for concern, according to a review in f1000 Medicine Reports.

28 Dec 2009

Scientists identify new gene variants associated with disturbances in lipid metabolism

Scientists of Helmholtz Zentrum München led by Professor Karsten Suhre have identified new gene variants associated with disturbances in the lipid metabolism.

28 Dec 2009

Publication validates company's structure-based approach for addressing undruggable targets

28 Dec 2009

Discovery of beta cell defending enzyme raises hope for new treatments against diabetes

Cells in your body are constantly churning out poisonous forms of oxygen (oxidants) and mopping them up with a countervailing force of proteins and chemicals (anti-oxidants).

28 Dec 2009

Forest Laboratories acquires additional rights to NXL 104 beta-lactamase inhibitor

Forest Laboratories announced today its agreement to acquire additional rights to NXL 104, which amends the terms of its prior agreement with Novexel covering the combination of NXL 104 with ceftaroline and adds additional rights to the combination of ceftazidime and NXL 104, through a transaction with AstraZeneca executed immediately following AstraZeneca’s announced acquisition of Novexel, S.A.

24 Dec 2009

Cardiac marker POC test: A successful concept of point-of-care diagnostics

Cardiac marker POC tests are now widely used in hospitals and have emerged as a successful model of the concept of point-of-care diagnostics, according to a new report from Kalorama Information. The 2008 world market for POC cardiac enzymes and tests is estimated at $490 million, and growing at 12% a year for the past three years, according to "Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads," from healthcare market research publisher Kalorama Information.

24 Dec 2009

VTT Innovation Program on food, nutrition and eating pattern

The objective of this roadmap was to feature the drivers, needs and future potential for various actors involved in the food production and distribution chain, but also for actors developing services offering communication and motivation tools for consumers who wish to improve their nutrition.

23 Dec 2009

Comprehensive up-date on pharmacology-assisted vitreoretinal surgery

Since the advent of pars plana vitrectomy, immense technical advances in the treatment of retinal diseases have been made. However, some mechanically based limitations of vitreoretinal surgery may result in incomplete removal of the vitreous, especially at the vitreoretinal interface and at the vitreous base. Here, pharmacology can be of assistance. For instance, enzymes that cleave the vitreoretinal junction without damaging the retina or which induce liquefaction may be applied.

23 Dec 2009

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

2009 saw exciting research progress, unprecedented opportunities on the horizon, and more scientists than ever working on resolving important questions. Despite the year's economic and financial challenges, the National Multiple Sclerosis Society continues to propel research forward to end MS. In 2009 the Society provided over $33.5 million to support 345 new and ongoing projects in its research portfolio, plus $1.5 million for Fast Forward, the Society's drug development subsidiary which continues to attract new funding streams.

23 Dec 2009

Reduced calories increase human cell lifespan

Going back for a second dessert after your holiday meal might not be the best strategy for living a long, cancer-free life say researchers from the University of Alabama at Birmingham. That's because they've shown exactly how restricted calorie diets-specifically in the form of restricted glucose-help human cells live longer. This discovery, published online in The FASEB Journal (http://www.fasebj.org) could help lead to drugs and treatments that slow human aging and prevent cancer.

23 Dec 2009

Enzyme dCK plays a profound role in normal lymphocyte development

Mice without the deoxycytidine kinase (dCK) enzyme have defects in their adaptive immune system, producing very low levels of both T and B lymphocytes, the major players involved in immune response, according to a study by researchers with UCLA's Jonsson Comprehensive Cancer Center.

23 Dec 2009

PGxHealth, DHZ announce collaboration in genetic variant study with response to clopidogrel

PGxHealth, a division of Clinical Data, Inc., today announced that it has established a research collaboration with Deutsches Herzzentrum (DHZ), Munich, Germany, to evaluate the predictive value of genetic markers, including PGxHealth proprietary markers, for response to clopidogrel (Plavix®).

22 Dec 2009

Enzyme News and Research

Anti-aromatase phytochemicals in pomegranates reduce hormone-dependent breast cancer

Anti-inflammatory prescription drug reduces the risk of common skin cancer in humans

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

UI cell membrane protein study may lead to new methods of tracking metastasizing cancer cells

Bacterial enzyme decreases cocaine desire

NeurAxon closes the sale of $8.75 million of unsecured subordinated convertible debentures

DMET genotyping platform screens for 1256 genetic variations in 170 genes

Emerald BioStructures engineers new allosteric small molecule modulators of the PDE4 enzyme

Sudden worldwide increase in antibiotic-resistant bacterium, a cause for concern

Scientists identify new gene variants associated with disturbances in lipid metabolism

Publication validates company's structure-based approach for addressing undruggable targets

Discovery of beta cell defending enzyme raises hope for new treatments against diabetes

Forest Laboratories acquires additional rights to NXL 104 beta-lactamase inhibitor

Cardiac marker POC test: A successful concept of point-of-care diagnostics

VTT Innovation Program on food, nutrition and eating pattern

Comprehensive up-date on pharmacology-assisted vitreoretinal surgery

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

Reduced calories increase human cell lifespan

Enzyme dCK plays a profound role in normal lymphocyte development

PGxHealth, DHZ announce collaboration in genetic variant study with response to clopidogrel

Biochemistry eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News